The effect of immunization of mothers on the antibody response of their young to pneumococcal type 19F polysaccharide was studied. When 2-week-old BALB/c mice from mothers immunized with 23-valent pneumococcal vaccine during gestation were given an additional dose of the same vaccine, mouse pneumococcal antiserum, or both, they produced higher titers of antibodies to the 19F polysaccharide (1.87 to 4 .66 ,ug of 19F immunoglobulin M [IgM] antibody per ml of serum; 0.45 to 0.81 ,ug of IgG antibody per ml of serum) than the control group that did not receive any treatment after birth (0.69 ,ug of 19F IgM antibody per ml; 0.28 ,ug of 19F IgG antibody per ml) (P < 0.01). Furthermore, all 11-to 12-week-old monkeys that received an additional dose of 23-valent vaccine, pneumococcal immunoglobulin, or both produced statistically higher titers of IgG antibody to the 19F polysaccharide than did controls at various ages. The titers (micrograms of IgG antibody per milliliter of serum) were as follows: vaccine group, 7.12 0.96; control group at 4 months of age, 3.82 0.74 (P < 0.01); immunoglobulin-treated group, 6 .85 0.76; vaccinated and immunoglobulin-treated group, 7 .80 + 1.40; control group at 3 months of age, 3 .01 ± 0.61 (P < 0.01). These results suggest that immunization of mothers under certain conditions, such as with an optimum dose of antigen at a critical period of gestation or postnatal development, could provide young infants with an enhanced antibody response to pneumococcal polysaccharide immunogens.
One of the most common Streptococcus pneumoniae types causing pneumococcal disease in young children is type 19F, which ranks 10th in frequency among all pneumococcal isolates (5, 20, 25, 28, 33) . Types 6, 14, 19F , and 23F account for 50 to 60% of pneumococcal isolates from infants and children (2) , whereas type 19F is the most prevalent type isolated from the middle ear fluid of children with acute otitis media (423 [23%] of 1,837 strains) (14) . Multiple antibiotic resistance has been reported in serotypes 19F, 19A, 3, 6, 14, and 23F (15, 16, 18, 26) . Type 19F polysaccharide (PS) is contained in the 23-valent pneumococcal vaccine. However, it has induced a low antibody response in young children. It is less stable than other types of pneumococcal PS in the vaccine (21 (19, 23) . Furthermore, combined passive immunization with immunoglobulin and active immunization of infant mice with monovalent PS may elicit sufficient 19F antibody formation for protection against infection during early life (23) . Maternal serum antibodies, including immunoglobulin M (IgM), IgG, and IgA, have been reported to be present in colostrum; these immunoglobulins, which are transferred to nursing neonates, are still largely intact (10 humoral antibodies and provided effective protection against infection (30, 32, 34 [7] ) and had a serum titer of greater than 1:64 as determined by immunodiffusion (29 (24, 36) . In brief, 19F PS was activated with cyanogen bromide at pH 10.5 for 6 min and reacted with 0.1 M 6-aminocaproic acid. The PS-6-aminocaproic acid complex and the membrane protein (50 mg per 10 ml in 0.1 M sodium acetate buffer [pH 5 .0]) were mixed, and coupling was carried out with 1-ethyl-3(3-dimethyl-amino propyl)-carbodiimide HCl (250 mg/ml) for 1 h at 4°C. The reaction mixture was passed through a Sepharose 4B column, and the void volume peak was retained. The concentrations of protein and PS, their ratios, and the molecular size profiles of the PS-protein conjugates were determined as described previously (22) .
Immunological methods. Antibody levels in serum were determined by a modified ELISA (9, 19, 37) . In brief, 0.1 ml of PS antigen (1 mg/ml) was added to 0.5 ml of 0.01 M sodium hydroxide solution. Next, 0.5 mg of cyanuric chloride and 0.1 ml of 0.1% poly-L-lysine were added. The solution was mixed thoroughly and kept at 4°C for 2 h and then adjusted to 1 jig of PS/ml in phosphate-buffered saline (PBS) (pH 7.4). Polystyrene microdilution plates were filled with 0.1 ml of PS-polylysine complex per well, kept at 4°C for 17 h, and washed with detergent solution (0.05% Brij) three times. The test antiserum samples were preabsorbed to remove cell wall PS antibody by adding 1 jig of cell wall PS to 1 ml of a 1:50 dilution of serum and incubated at 25°C for 60 min. Mouse and monkey antiserum standards and/or antiserum samples diluted 1/100 to 1/300 in PBS containing 5% fetal calf serum and 0.01% sodium azide were added to plates and mixed with shaking at 25°C for 2 h. Alkaline phosphatase conjugated to rabbit anti-mouse IgG or IgM and diluted 1/1,000 in PBS was added to each well. The microdilution plates were returned to the shaker for 2 h. After the plates were washed, 1-mg/ml p-nitrophenyl phosphate in 1 M Tris buffer (pH 9.8) containing 0.3 mM magnesium chloride was added to each well. After 30 or 60 min, the reaction was stopped by the addition of 0.05 ml of 4 N sodium hydroxide. The optical density was measured spectrophotometrically at 405 nm. The ELISA for measuring monkey IgG antibody was performed under similar conditions with peroxidase conjugated with goat anti-monkey IgG antibody and o-phenylenediamine as the substrate.
The effects of coating the microdilution plates with PSpolylysine complex, sample antibody concentration, duration of incubation, and temperature were studied to determine the optimum conditions for the ELISA. The PS antigen-antibody reaction by the alkaline phosphatase-conjugated mouse IgM or IgG activity was optimum when microdilution plates were coated with 1 jig of PS per ml and kept at 4°C for 17 h. The standard curves of mouse IgM and Figure 1 shows the experimental design for the evaluation of the effect of immunization of mothers and passive immunity on the antibody response of young infants. Pregnant mice at 2 weeks of gestation were given the following subcutaneous injections: the first group received a 23-valent pneumococcal vaccine (0.5 jig of each PS in 0.2 ml), the second group received 0.2 ml of mouse pneumococcal antiserum, and the third group received the same amount of saline. Fourteen days after birth, young mice were given one of the following treatments intraperitoneally (i.p.): (i) saline (0.1 ml), (ii) pneumococcal vaccine (0.1 jig of each PS in 0.1 ml), (iii) mouse pneumococcal antiserum (0.1 ml of a 1/10 dilution), or (iv) both vaccine and antiserum (ii and iii) given at different sites. In another experiment, groups of eight pregnant mice received the vaccine (0.5 jig of each PS in 0.2 ml) at 14 days of gestation. Fourteen days after birth, young mice were given one of the following treatments i.p.: (i) saline (0.1 ml), (ii) meningococcal group A PS (0.1 jig per 0.1 ml), (iii) rabbit meningococcal group A antiserum (1/10 dilution, 0.1 ml), or (iv) normal mouse antiserum (0.1 ml of a 1/10 dilution). Seven days later, serum samples from all young mice were obtained, and the antibody levels were determined by using the ELISA.
(ii) Monkey study. Some experiments conducted in the mouse study were further examined by using monkeys (Fig.  2) . Altogether, 40 ,ug/ml. At delivery, the 19F antibody increased to 5 to 5.9 ,ug/ml, a 2.7-to 4.6-fold increase in antibody titer. The 19F antibody levels in serum remained at elevated levels for several months and then gradually decreased. Six months after vaccination, the IgG antibody titers were 1.4 to 2.7 times the preimmunization levels.
The IgG antibody responses of young monkeys to 19F PS are shown in Fig. 4B . At birth, the infants had 19F IgG antibody levels of 3 to 4 ,ug/ml, slightly lower than the antibody level of the mothers. The 19F antibody levels in the control group gradually decreased over 6 months. Young monkeys that received an additional dose of vaccine had significantly higher 19F antibody titers at 4 months of age than did the control group. Those that received pneumococcal immunoglobulin at 11 weeks of age had significantly elevated antibody titers at 12 weeks; the titers gradually decreased over 6 months. The group that received immunoglobulin plus the vaccine showed the highest 19F antibody response at 4 months of age. The antibody titer was 2.3-fold higher than that of the control group. At 3, 4, and 6 months of age, the antibody titers from the group that received immunoglobulin plus the vaccine were higher than that of the control group.
DISCUSSION
Most bacterial PSs do not induce significant antibody formation when given to infants. A possible means whereby infants could be protected from these infections in early life is through immunization of the mothers during gestation, with the development of high IgG antibody levels in serum that can be transferred to the infant through the placenta and the mother's milk. For example, infants born of mothers with high levels of specific antibodies to group B streptococcal type III PS are less susceptible to type III infection than are other infants (3). Passive immunization was reported to be effective for treatment of pneumococcal, meningococcal, and Haemophilus influenzae type b infections (38) . Furthermore, passive immunization combined with active immunization induced high antibody responses in neonates (11, 40) and may be applicable to the prevention of bacterial infections.
Recently, many studies have supported a concept that the neonatal immune system is susceptible to regulation by anti-idiotypic antibodies (31, 35) . Priming effects of maternal anti-idiotypes have been transmitted in milk (39) , and in utero sensitization to transferred antibodies has been induced (27) . These studies have indicated that anti-idiotypic antibodies or idiotypes (primary antibodies) can cross the placenta and alter the immune response of offspring. Maternal antibodies and anti-idiotypic antibodies can prime the infants for protection against a bacterial infection; e.g., infants whose mothers were immunized with tetanus toxoid Mean antibody levels + standard errors between subgroups were compared by using a two-tailed Student t test. The antibody responses of young from pregnant mice immunized with pneumococcal vaccine (group I), antiserum (group II), or saline (group III) that received an additional dose of vaccine (Vacc), antiserum (AS) or vaccine plus antiserum were compared with those of young mice receiving no treatment (-). *, P < 0.05; **, P < 0.01. Each group consisted of six to eight animals. during pregnancy responded better to subsequent immunization than did infants of nonimmunized mothers (8) Injection of pregnant mice with pneumococcal vaccine induced 6.8-and 2.9-fold IgG and IgM antibody responses, respectively, in young that received an additional dose of vaccine after birth. However, less antibody (2.2-and 1.8-fold increases in IgG and IgM antibodies, respectively) was observed in these infants from mothers given pneumococcal antiserum. Offspring of mothers that received saline also produced a low antibody response (1.9-and 1.6-fold increases in IgG and IgM antibodies, respectively). Regarding the comparison of the antibody responses in offspring whose mothers received antisera and saline, these serum samples were analyzed by using the ELISA at different times; thus they should not be compared directly for their antibody levels.
Similar to the results with the monkey model, there was an enhancement of antibody production in mouse offspring from immunized mothers that received additional pneumococcal vaccine and antiserum (3.94 
